Jazz Pharmaceuticals (JAZZ) PT Raised to $201 at BMO Capital
Tweet Send to a Friend
BMO Capital raised its price target on Jazz Pharmaceuticals (NASDAQ: JAZZ) to $201.00 (from $199.00) while maintaining an Outperform rating.Analyst ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
